ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Johan Maertens; Simone Cesaro; Georg Maschmeyer; Hermann Einsele; J. Peter Donnelly; Alexandre Alanio; Philippe M. Hauser; Katrien Lagrou; Willem J.G. Melchers; Jannik Helweg-Larsen; Olga Matos; Stéphane Bretagne; Catherine Cordonnier; Samir Agrawal; Christopher Kibbler; Antonio Pagliuca; Katherine Ward; Murat Akova; Raoul Herbrecht; Vincent Mallet; Patricia Ribaud; Mahmoud Aljurf; Dina Averbuch; Dan Engelhard; Thomas Berg; Oliver Cornely; Olaf Penack; Florian van Boemmel; Marie von Lilienfeld-Toal; Ola Blennow; Per Ljungman; Roger Bruggemann; Peter Donnelly; Bart Jan Kullberg; Willem Melchers; Thierry Calandra; Hans Hirsch; Oscar Marchetti; Christina Orasch; Frederic Tissot; Elio Castagnola; Corrado Girmenia; Malgorzata Mikulska; Livio Pagano; Claudio Viscoli; Rafael De La Camara; Rafael Duarte; Patricia Munoz; Lubos Drgona; Ruth Hargreaves; Petr Hubacek; Michal Kouba; Zdenek Racil; Galina Klyasova; George Pettrikos; Emmanuel Roilides; Anna Skiada; Valérie Rizzi-Puechal; Janos Sinko; Monica Slavin; Jan Styczynski; Lorraine Tweddle; Craig Wood

doi:10.1093/jac/dkw157

ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Johan Maertens, Simone Cesaro, Georg Maschmeyer, Hermann Einsele, J. Peter Donnelly, Alexandre Alanio, Philippe M. Hauser, Katrien Lagrou, Willem J.G. Melchers, Jannik Helweg-Larsen, Olga Matos, Stéphane Bretagne, Catherine Cordonnier, Samir Agrawal, Christopher Kibbler, Antonio Pagliuca, Katherine Ward, Murat Akova, Raoul Herbrecht, Vincent MalletPatricia Ribaud, Mahmoud Aljurf, Dina Averbuch, Dan Engelhard, Thomas Berg, Oliver Cornely, Olaf Penack, Florian van Boemmel, Marie von Lilienfeld-Toal, Ola Blennow, Per Ljungman, Roger Bruggemann, Peter Donnelly, Bart Jan Kullberg, Willem Melchers, Thierry Calandra, Hans Hirsch, Oscar Marchetti, Christina Orasch, Frederic Tissot, Elio Castagnola, Corrado Girmenia, Malgorzata Mikulska, Livio Pagano, Claudio Viscoli, Rafael De La Camara, Rafael Duarte, Patricia Munoz, Lubos Drgona, Ruth Hargreaves, Petr Hubacek, Michal Kouba, Zdenek Racil, Galina Klyasova, George Pettrikos, Emmanuel Roilides, Anna Skiada, Valérie Rizzi-Puechal, Janos Sinko, Monica Slavin, Jan Styczynski, Lorraine Tweddle, Craig Wood

Group Tissing

Research output: Contribution to journal › Review article › peer-review

241 Citations (Scopus)

Abstract

The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/ sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatmentwith corticosteroids andwell-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Original language	English
Pages (from-to)	2397-2404
Number of pages	8
Journal	Journal of Antimicrobial Chemotherapy
Volume	71
Issue number	9
DOIs	https://doi.org/10.1093/jac/dkw157
Publication status	Published - 1 Sept 2016

Access to Document

10.1093/jac/dkw157

Cite this

Maertens, J., Cesaro, S., Maschmeyer, G., Einsele, H., Donnelly, J. P., Alanio, A., Hauser, P. M., Lagrou, K., Melchers, W. J. G., Helweg-Larsen, J., Matos, O., Bretagne, S., Cordonnier, C., Agrawal, S., Kibbler, C., Pagliuca, A., Ward, K., Akova, M., Herbrecht, R., ... Wood, C. (2016). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy, 71(9), 2397-2404. https://doi.org/10.1093/jac/dkw157

@article{98b6bbd3f6054a39ab634c195694088b,

title = "ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients",

abstract = "The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/ sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatmentwith corticosteroids andwell-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.",

author = "Johan Maertens and Simone Cesaro and Georg Maschmeyer and Hermann Einsele and Donnelly, {J. Peter} and Alexandre Alanio and Hauser, {Philippe M.} and Katrien Lagrou and Melchers, {Willem J.G.} and Jannik Helweg-Larsen and Olga Matos and St{\'e}phane Bretagne and Catherine Cordonnier and Samir Agrawal and Christopher Kibbler and Antonio Pagliuca and Katherine Ward and Murat Akova and Raoul Herbrecht and Vincent Mallet and Patricia Ribaud and Mahmoud Aljurf and Dina Averbuch and Dan Engelhard and Thomas Berg and Oliver Cornely and Olaf Penack and {van Boemmel}, Florian and {von Lilienfeld-Toal}, Marie and Ola Blennow and Per Ljungman and Roger Bruggemann and Peter Donnelly and Kullberg, {Bart Jan} and Willem Melchers and Thierry Calandra and Hans Hirsch and Oscar Marchetti and Christina Orasch and Frederic Tissot and Elio Castagnola and Corrado Girmenia and Malgorzata Mikulska and Livio Pagano and Claudio Viscoli and {De La Camara}, Rafael and Rafael Duarte and Patricia Munoz and Lubos Drgona and Ruth Hargreaves and Petr Hubacek and Michal Kouba and Zdenek Racil and Galina Klyasova and George Pettrikos and Emmanuel Roilides and Anna Skiada and Val{\'e}rie Rizzi-Puechal and Janos Sinko and Monica Slavin and Jan Styczynski and Lorraine Tweddle and Craig Wood",

note = "Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2016",

month = sep,

day = "1",

doi = "10.1093/jac/dkw157",

language = "English",

volume = "71",

pages = "2397--2404",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "9",

}

Maertens, J, Cesaro, S, Maschmeyer, G, Einsele, H, Donnelly, JP, Alanio, A, Hauser, PM, Lagrou, K, Melchers, WJG, Helweg-Larsen, J, Matos, O, Bretagne, S, Cordonnier, C, Agrawal, S, Kibbler, C, Pagliuca, A, Ward, K, Akova, M, Herbrecht, R, Mallet, V, Ribaud, P, Aljurf, M, Averbuch, D, Engelhard, D, Berg, T, Cornely, O, Penack, O, van Boemmel, F, von Lilienfeld-Toal, M, Blennow, O, Ljungman, P, Bruggemann, R, Donnelly, P, Kullberg, BJ, Melchers, W, Calandra, T, Hirsch, H, Marchetti, O, Orasch, C, Tissot, F, Castagnola, E, Girmenia, C, Mikulska, M, Pagano, L, Viscoli, C, De La Camara, R, Duarte, R, Munoz, P, Drgona, L, Hargreaves, R, Hubacek, P, Kouba, M, Racil, Z, Klyasova, G, Pettrikos, G, Roilides, E, Skiada, A, Rizzi-Puechal, V, Sinko, J, Slavin, M, Styczynski, J, Tweddle, L & Wood, C 2016, 'ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients', Journal of Antimicrobial Chemotherapy, vol. 71, no. 9, pp. 2397-2404. https://doi.org/10.1093/jac/dkw157

TY - JOUR

T1 - ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

AU - Maertens, Johan

AU - Cesaro, Simone

AU - Maschmeyer, Georg

AU - Einsele, Hermann

AU - Donnelly, J. Peter

AU - Alanio, Alexandre

AU - Hauser, Philippe M.

AU - Lagrou, Katrien

AU - Melchers, Willem J.G.

AU - Helweg-Larsen, Jannik

AU - Matos, Olga

AU - Bretagne, Stéphane

AU - Cordonnier, Catherine

AU - Agrawal, Samir

AU - Kibbler, Christopher

AU - Pagliuca, Antonio

AU - Ward, Katherine

AU - Akova, Murat

AU - Herbrecht, Raoul

AU - Mallet, Vincent

AU - Ribaud, Patricia

AU - Aljurf, Mahmoud

AU - Averbuch, Dina

AU - Engelhard, Dan

AU - Berg, Thomas

AU - Cornely, Oliver

AU - Penack, Olaf

AU - van Boemmel, Florian

AU - von Lilienfeld-Toal, Marie

AU - Blennow, Ola

AU - Ljungman, Per

AU - Bruggemann, Roger

AU - Donnelly, Peter

AU - Kullberg, Bart Jan

AU - Melchers, Willem

AU - Calandra, Thierry

AU - Hirsch, Hans

AU - Marchetti, Oscar

AU - Orasch, Christina

AU - Tissot, Frederic

AU - Castagnola, Elio

AU - Girmenia, Corrado

AU - Mikulska, Malgorzata

AU - Pagano, Livio

AU - Viscoli, Claudio

AU - De La Camara, Rafael

AU - Duarte, Rafael

AU - Munoz, Patricia

AU - Drgona, Lubos

AU - Hargreaves, Ruth

AU - Hubacek, Petr

AU - Kouba, Michal

AU - Racil, Zdenek

AU - Klyasova, Galina

AU - Pettrikos, George

AU - Roilides, Emmanuel

AU - Skiada, Anna

AU - Rizzi-Puechal, Valérie

AU - Sinko, Janos

AU - Slavin, Monica

AU - Styczynski, Jan

AU - Tweddle, Lorraine

AU - Wood, Craig

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/ sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatmentwith corticosteroids andwell-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

AB - The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/ sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatmentwith corticosteroids andwell-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

UR - http://www.scopus.com/inward/record.url?scp=84991610745&partnerID=8YFLogxK

U2 - 10.1093/jac/dkw157

DO - 10.1093/jac/dkw157

M3 - Review article

C2 - 27550992

AN - SCOPUS:84991610745

SN - 0305-7453

VL - 71

SP - 2397

EP - 2404

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 9

ER -

ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Abstract

Access to Document

Fingerprint

Cite this